NOVEL PERSPECTIVES ON THE CONTRIBUTORS TO INFLAMMATORY BOWEL DISEASE DEVELOPMENT

Authors

  • FA KIANI Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan
  • AA FAROOQ Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan
  • MA JAVID Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan & Faculty of Animal Husbandry & Veterinary Sciences, Sindh Agriculture University, Tandojam, Pakistan
  • MU SALEEM Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan
  • Z AHMED Faculty of Veterinary & Animal Sciences, University of Poonch, Rawalakot, Azad Kashmir, Pakistan
  • F RASOOL Faculty of Veterinary & Animal Sciences, University of Poonch, Rawalakot, Azad Kashmir, Pakistan
  • S KHAN Faculty of Veterinary & Animal Sciences, Lasbela University of Agriculture, Water & Marine Sciences, Uthal, Baluchistan
  • M NAWAZ Faculty of Veterinary & Animal Sciences, University of Poonch, Rawalakot, Azad Kashmir, Pakistan
  • MS AZEEM Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan
  • K MEHMOOD Faculty of Veterinary and Animal Sciences, Islamia University Bahawalpur 63100, Pakistan.

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1362

Keywords:

Inflammatory bowel disease, gut microbiome, Crohn's disease, ulcerative colitis

Abstract

Irritable bowel disease (IBD), commonly referred to as Crohn's disease (CD) and ulcerative colitis (UC), is a persistent and recurring inflammation of the gastrointestinal tract (GIT). Despite the increasing prevalence of IBD globally, its precise aetiology remains unidentified, and no definitive treatment or cure has been established. The intricate interplay among environmental influences, genetics, and the host's immune system is believed to be the primary aetiology of IBD. Recent advancements in next-generation sequencing technologies indicate that IBD is linked to alterations in the function and composition of the gut microbiota, called dysbiosis. Experimental and clinical evidence suggests that dysbiosis plays a crucial part in the onset of IBD. Despite extensive investigations aimed at identifying new pathogenic factors related to IBD, encompassing environmental, genetic, microbial, and immune response elements, a comprehensive knowledge of IBD aetiology still needs to be identified as the treatment for IBD patients requires improved outcomes. A more profound comprehension of the disease's aetiology may yield distinctive insights applicable to developing therapeutic strategies for IBD. Recent research has markedly enhanced our understanding of the pathobiology of IBD, resulting in substantial progress in its diagnosis and treatment. We have emphasized current advancements and discoveries about emerging elements that contribute to disease pathogenesis, such as gut microbiota, which significantly influence the aetiology of IBD and may serve as prospective targets for innovative therapeutics in IBD patients.

Downloads

Download data is not yet available.

References

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307-17.

Zeissig S, Petersen B-S, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015;64(12):1889-97.

Benhayon D, Youk A, McCarthy FN, Davis S, Keljo DJ, Bousvaros A, et al. Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. Journal of pediatric gastroenterology and nutrition. 2013;57(3):335-42.

Bergamaschi G, Castiglione F, D’Incà R, Astegiano M, Fries W, Milla M, et al. Prevalence, pathogenesis and management of anemia in inflammatory bowel disease: an IG-IBD multicenter, prospective, and observational study. Inflammatory Bowel Diseases. 2023;29(1):76-84.

Thomas JP, Modos D, Rushbrook SM, Powell N, Korcsmaros T. The emerging role of bile acids in the pathogenesis of inflammatory bowel disease. Frontiers in immunology. 2022;13:829525.

Nikolakis D, de Voogd FA, Pruijt MJ, Grootjans J, van de Sande MG, D’haens GR. The role of the lymphatic system in the pathogenesis and treatment of inflammatory bowel disease. International journal of molecular sciences. 2022;23(3):1854.

Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. Journal of gastroenterology. 2013;48:315-21.

Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical journal of gastroenterology. 2018;11:1-10.

Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313-21. e2.

Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, et al. RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009;136(1):257-67.

Abdullah N, Defaye M, Altier C. Neural control of gut homeostasis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2020;319(6):G718-G32.

Vernia F, Valvano M, Longo S, Cesaro N, Viscido A, Latella G. Vitamin D in inflammatory bowel diseases. Mechanisms of action and therapeutic implications. Nutrients. 2022;14(2):269.

Liu JZ, Van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature genetics. 2015;47(9):979-86.

Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. Journal of gastroenterology. 2014;49:785-98.

Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. Journal of gastroenterology. 2015;50:495-507.

Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annual review of immunology. 2012;30(1):759-95.

Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflammatory bowel diseases. 2007;13(8):955-62.

Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease. Digestion. 1960;93(1):59-65.

O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO reports. 2006;7(7):688-93.

LeBlanc J, Laiño JE, Del Valle MJ, Vannini V, van Sinderen D, Taranto MP, et al. B‐Group vitamin production by lactic acid bacteria–current knowledge and potential applications. Journal of applied microbiology. 2011;111(6):1297-309.

Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. Journal of gastroenterology. 2017;52:1-8.

Pomare E, Branch W, Cummings J. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. The Journal of clinical investigation. 1985;75(5):1448-54.

Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiology and molecular biology reviews. 1998;62(4):1157-70.

Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nature reviews immunology. 2009;9(5):313-23.

Kamada N, Núñez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology. 2014;146(6):1477-88.

Bouskra D, Brézillon C, Bérard M, Werts C, Varona R, Boneca IG, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008;456(7221):507-10.

Hapfelmeier S, Lawson MA, Slack E, Kirundi JK, Stoel M, Heikenwalder M, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328(5986):1705-9.

Umesaki Y, Okada Y, Matsumoto S, Imaoka A, Setoyama H. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex‐germ‐free mouse. Microbiology and immunology. 1995;39(8):555-62.

Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677-89.

Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578-93.

Shanahan F. The host–microbe interface within the gut. Best practice & research Clinical gastroenterology. 2002;16(6):915-31.

Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140(6):845-58.

Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. cell. 2008;133(5):775-87.

Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163(2):367-80.

Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiological reviews. 2010.

Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology. 2013;13(11):790-801.

Kamada N, Kim Y-G, Sham HP, Vallance BA, Puente JL, Martens EC, et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science. 2012;336(6086):1325-9.

Huang T, Zhang X, Pan J, Su X, Jin X, Guan X. Purification and characterization of a novel cold shock protein-like bacteriocin synthesized by Bacillus thuringiensis. Scientific reports. 2016;6(1):35560.

Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG. Bacterial flagellin stimulates toll-like receptor 5—dependent defense against vancomycin-resistant Enterococcus infection. The Journal of infectious diseases. 2010;201(4):534-43.

Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008;455(7214):804-7.

Talham GL, Jiang H-Q, Bos NA, Cebra JJ. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infection and immunity. 1999;67(4):1992-2000.

Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the national academy of sciences. 2007;104(34):13780-5.

Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC microbiology. 2011;11:1-12.

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55(2):205-11.

Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, et al. Colonisation by F aecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Alimentary pharmacology & therapeutics. 2013;38(2):151-61.

Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. The ISME journal. 2007;1(5):403-18.

Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell host & microbe. 2008;3(6):417-27.

Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A-L, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127(2):412-21.

Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, metabolome and inflammatory bowel disease. Microorganisms. 2016;4(2):20.

van der Waaij LA, Harmsen HJ, Madjipour M, Kroese FG, Zwiers M, Van Dullemen H, et al. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflammatory bowel diseases. 2005;11(10):865-71.

Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augmentin vitroutilization of mucin by other bacteria. Official journal of the American College of Gastroenterology| ACG. 2010;105(11):2420-8.

Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232-6.

Loubinoux J, Bronowicki J-P, Pereira IA, Mougenel J-L, Le Faou AE. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS microbiology ecology. 2002;40(2):107-12.

Zinkevich V, Beech IB. Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. FEMS microbiology ecology. 2000;34(2):147-55.

Rowan F, Docherty NG, Murphy M, Murphy B, Coffey JC, O‘Connell PR. Desulfovibrio bacterial species are increased in ulcerative colitis. Diseases of the Colon & Rectum. 2010;53(11):1530-6.

Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. The American journal of clinical nutrition. 2001;73(2):361s-4s.

Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617-23.

Mardini HE, Grigorian AY. Probiotic mix VSL# 3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflammatory bowel diseases. 2014;20(9):1562-7.

Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical gastroenterology and hepatology. 2009;7(11):1202-9. e1.

Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary pharmacology & therapeutics. 2006;23(11):1567-74.

Mallon PT, McKay D, Kirk SJ, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 2007(4).

Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842-7.

Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? Journal of clinical gastroenterology. 1997;25(4):653-8.

Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digestive diseases and sciences. 2000;45:1462-4.

Shen J, Zuo Z-X, Mao A-P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflammatory bowel diseases. 2014;20(1):21-35.

Quraishi MN, Widlak M, Bhala Na, Moore D, Price M, Sharma N, et al. Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary pharmacology & therapeutics. 2017;46(5):479-93.

Downloads

Published

2024-12-24

How to Cite

KIANI, F., FAROOQ, A., JAVID, M., SALEEM, M., AHMED, Z., RASOOL, F., KHAN, S., NAWAZ, M., AZEEM, M., & MEHMOOD, K. (2024). NOVEL PERSPECTIVES ON THE CONTRIBUTORS TO INFLAMMATORY BOWEL DISEASE DEVELOPMENT. Biological and Clinical Sciences Research Journal, 2024(1), 1362. https://doi.org/10.54112/bcsrj.v2024i1.1362

Most read articles by the same author(s)

1 2 3 4 > >>